亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Failure to use new breakthrough treatments for epilepsy

Dravet综合征 医学 癫痫 芬氟拉明 左乙拉西坦 不利影响 Lennox-Gastaut综合征 安慰剂 随机对照试验 儿科 麻醉 内科学 精神科 替代医学 血清素 受体 病理
作者
Pavel Klein,Gregory L. Krauss,Bernhard Jochen Steinhoff,Orrin Devinsky,Michael R. Sperling
出处
期刊:Epilepsia [Wiley]
卷期号:64 (6): 1458-1465 被引量:50
标识
DOI:10.1111/epi.17564
摘要

Despite the approval of ~20 additional antiseizure medications (ASMs) since the 1980s, one-third of epilepsy patients experience seizures despite therapy. Drug-resistant epilepsy (DRE) is associated with cognitive and psychiatric comorbidities, socioeconomic impairment, injuries, and a 9.3-13.4 times higher mortality rate than in seizure-free patients. Improved seizure control can reduce morbidity and mortality. Two new ASMs were launched in the United States in 2020: cenobamate for focal epilepsy in adults and fenfluramine for Dravet syndrome (DS). They offer markedly improved efficacy. Cenobamate achieved 21% seizure freedom with the highest dose and decreased tonic-clonic seizures by 93% during maintenance treatment in a randomized clinical trial (RCT). In long-term, open-label studies, 10%-36% of patients were seizure-free for a median duration of ~30-45 months. Fenfluramine treatment in DS reduced convulsive seizure frequency by 56% over placebo at the highest dose, with 8% of patients free of convulsive seizures, and 25% with only one convulsive seizure over 14 weeks. These results were sustained for up to 3 years in open-label extension studies. Mortality was reduced 5-fold. These results are superior to all other approved ASMs, placing these two drugs among the most effective antiseizure therapies. The adverse event profiles resemble those of other ASMs. Despite greater efficacy and similar toxicity, these medications are infrequently used. Two years after US market entry, < 5% of either adults with focal DRE or patients with DS were treated with either cenobamate or fenfluramine. We believe this is a failure of our medical system, resulting from limited knowledge about these drugs stemming partly from the separation of academia from industry; restrictions to access created by health care payors, hospitals, and regulatory agencies; and insufficient post-launch information about the efficacy and safety of these ASMs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
正在输入中完成签到 ,获得积分10
2秒前
Ziezer完成签到,获得积分10
3秒前
YueLi完成签到 ,获得积分10
6秒前
聪慧哈密瓜完成签到 ,获得积分10
6秒前
gly完成签到,获得积分10
7秒前
小白加油完成签到 ,获得积分10
9秒前
爆米花的应助被初景采纳,获得10
10秒前
Sissi发布了新的文献求助10
10秒前
孤独的芹菜完成签到,获得积分10
16秒前
Techmarine完成签到,获得积分10
20秒前
24秒前
27秒前
Cpp完成签到 ,获得积分10
28秒前
28秒前
如意行天完成签到 ,获得积分10
28秒前
30秒前
小林太郎发布了新的文献求助100
32秒前
Lucas的应助被张世琪采纳,获得10
33秒前
红宝石设计局完成签到,获得积分10
33秒前
34秒前
15735802374完成签到 ,获得积分10
35秒前
卓涛完成签到,获得积分10
39秒前
哇咔咔发布了新的文献求助10
41秒前
42秒前
chifan完成签到 ,获得积分10
43秒前
诚心铅笔完成签到,获得积分10
44秒前
过眼云烟完成签到,获得积分10
45秒前
45秒前
张世琪发布了新的文献求助10
46秒前
48秒前
48秒前
D4C发布了新的文献求助20
50秒前
53秒前
高高的网络完成签到,获得积分10
54秒前
哇咔咔完成签到,获得积分10
54秒前
null的应助被科研通管家采纳,获得10
55秒前
null的应助被科研通管家采纳,获得10
55秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
56秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
56秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179680
求助须知:如何正确求助?哪些是违规求助? 9569938
关于积分的说明 21807764
捐赠科研通 7775242
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557044
邀请新用户注册赠送积分活动 2478783